Name | Pentagamavunon-1 |
Synonyms | Pentagamavunon-1 |
CAS | 27060-70-4 |
Molecular Formula | C23H24O3 |
Molar Mass | 348.43 |
Appearance | Solid |
Storage Condition | 2-8°C,密封,干燥 |
biological activity | Pentagamavunon-1 (PGV-1) is an analog of currumin with oral activity, apoptosis signals are induced by multiple mechanisms, such as inhibition of COX-2 and VEGF. Pentagamavunon-1 (PGV-1) inhibited the activation of NF-κB. |
Cell Line: | Human colon carcinoma WiDr. WiDr cells. |
Concentration: | 1, 2.5, 5, 7.5, 10, 15, and 20 µM. 1, 2.5, 5, and 10 µM. |
Incubation Time: | 6, 12, 24, and 48 hours. 24 h. |
Result: | Significantly enhanced the cytotoxicity of 5-FU on WiDr cells at various concentrations during 6, 12, 24, and 48 h incubation. The non-treated WiDr cells showed cell accumulation in G1, S, and G2/M phase about 50.85%, 36.11% and 13.04%, respectively. Exhibited little decrease in body weight, nor a decrease in white and red blood cell counts in peripheral blood, nor any other efects in behavior and macroscopic appearance. Thus, PGV-1 was sufciently potent to suppress tumor formation in vivo, but exhibited little or no obvious adverse effects on the normal lineage of cells. |
Animal Model: | Human cancer cells in a xenograf mouse model. |
Dosage: | 20mg/kg. |
Administration: | P.O. every 2 days for 20 days. |